ConcertAI is a Cambridge, MA-based provider of enterprise AI and real-world data (RWD) solutions for life sciences and healthcare. The company offers software-as-a-service (SaaS) and data solutions to life sciences and biopharma companies, healthcare providers, contract research organizations (CROs), medical societies, and regulators in the US, Europe, and Japan. Through a “system of evidence” approach, ConcertAI advances data and technologies that underpin new models of clinical development, driven by the pandemic’s acceleration to fully digital and AI-enabled solutions. Its assets include a large, independent oncology research database and patient data composed of clinical, molecular, medical claims, and imaging data. Led by CEO Jeff Elton, PhD., and Executive Chairman Dr. Romesh Wadhwani, the company has expanded its customer base and partnerships to more than 45 life sciences companies and CROs over the past 36 months. Oncology biopharma companies including Janssen and BMS are cited as multi-product strategic partners. The company intends to use the new funding to expand operations and broaden its business reach. Concerto HealthAI provides Real-World Data (RWD) and AI-enabled enterprise technology for precision oncology, assembling a clinical network through partnerships with community oncology networks and an exclusive license with CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology. Its data integrations span all major electronic medical record environments and include next-generation sequencing diagnostic information and patient-reported outcomes. The company’s engineers produce case-aligned, AI-enriched, validated, production-ready RWD products and complementary AI-enabled cloud technologies for precision research and patient solutions. Concerto recently launched a new version of eurekaHealth that combines integrated RWD with advanced machine learning. The company intends to use recent funding to support continued innovation in RWD and technology products and services for regulatory and non-regulatory applications, expansion into adjacent therapy areas, and commercial patient solutions. Concerto HealthAI is based in Boston, MA.

Total raised

$300M

Funding rounds

2

Latest round

Series C

Latest activity

Mar 2022